Gene therapy breakthrough for rare kidney disease enters human trials
Disease control
Recruiting now
This study tests a new gene therapy called ABO-101 for people with Primary Hyperoxaluria Type 1 (PH1), a rare genetic disorder that causes kidney stones and kidney damage. The trial will first test single doses in adults to find the safest dose, then test that dose in children. R…
Phase: PHASE1, PHASE2 • Sponsor: Arbor Biotechnologies • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC